Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-03-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关联方占用资金情况的专项审计说明（2018年度）
Audit Report / Information Classification · 95% confidence The document is a specialized audit report concerning related party fund occupation for the fiscal year 2018 of Xiamen Aide Biomedical Technology Co., Ltd. It includes an auditor's opinion, references to regulatory requirements from the China Securities Regulatory Commission, and detailed financial tables about non-operating fund occupation and related party transactions. The document is titled as a "special audit explanation" and contains audit procedures, responsibilities, and conclusions. It is not a full annual report, nor a general audit report of financial statements, but a standalone audit report focused on a specific regulatory compliance issue. The document length is about 2598 characters, which is sufficient for a detailed audit opinion but not a full annual report. Therefore, the best fitting category is Audit Report / Information (AR). FY 2018
2019-03-25 Chinese
募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report (鉴证报告) for the year 2018 concerning the company's raised funds (募集资金) storage and usage. It includes auditor responsibilities, verification procedures, and an audit conclusion stating compliance with regulatory requirements for the management and use of raised funds. The report contains detailed financial data on the amount raised, usage, balance, investment projects, changes in fund usage, and related approvals by the board and shareholders. It references specific regulatory guidelines and includes auditor certification. The document is not a full annual report (10-K), nor a general audit report (AR) of financial statements, but a specialized audit/verification report focused on the use of raised capital. It is not an announcement or a brief summary but a substantive verification report with financial details. Therefore, it fits best under Audit Report / Information (AR). FY 2018
2019-03-25 Chinese
独立董事2018年度述职报告（蔡宁）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2018 Annual Work Report" from Xiamen Aide Biomedical Technology Co., Ltd. It is a detailed narrative by an independent director about their activities, attendance at board meetings, opinions on various company matters, committee work, and efforts to protect investor rights during the 2018 fiscal year. The document is a report on the director's duties and activities rather than a financial report, audit, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement or proxy solicitation. It is a management-related report focusing on board and governance activities, specifically the independent director's annual report. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 2729 characters, which is consistent with a detailed report but not a full annual report or audit report. Confidence is high given the clear nature of the document as an independent director's annual work report.
2019-03-25 Chinese
关于2018年年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (328 characters) from a company about the disclosure of its 2018 annual report. It states that the annual report and its summary have been disclosed on a regulatory website and advises investors to review it. There is no actual financial data or detailed report content included, only a notification of the report's availability. According to the 'MENU VS MEAL' rule, such a brief notice about the report's publication is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2019-03-25 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes detailed descriptions of internal control evaluations, management responsibilities, auditor responsibilities, and conclusions on the effectiveness of internal controls related to financial reporting as of December 31, 2018. It is issued by a registered accounting firm and includes a self-evaluation report by the company on internal controls. The content focuses on internal control assessment and assurance rather than full financial statements or annual performance. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control assessments, excluding full annual reports. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-03-25 Chinese
中信证券股份有限公司关于公司2018年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. regarding the 2018 annual special inspection of the deposit and use of raised funds by Xiamen Aide Biomedical Technology Co., Ltd. It includes specific financial figures about the amount raised, usage, balance, investment projects, changes in fund usage, and compliance with regulatory requirements. The document references regulatory approvals, audit opinions from an accounting firm, and compliance with listing rules and securities regulations. It is a standalone audit and verification report focused on the management and use of raised funds, not a full annual report or earnings release. It does not present comprehensive financial statements or management discussion of overall company performance but focuses on the audit and verification of fundraising usage. Therefore, it fits the category of an Audit Report / Information (AR). The document length (8986 characters) and detailed financial data support this classification with high confidence. FY 2018
2019-03-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.